Trade Stoke Therapeutics, Inc. - STOK CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 11.67 |
| Open | 12.14 |
| 1-Year Change | 24.51% |
| Day's Range | 11.6 - 12.38 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 2, 2024 | 11.67 | 0.13 | 1.13% | 11.54 | 11.96 | 11.20 |
| May 1, 2024 | 11.52 | 0.52 | 4.73% | 11.00 | 11.78 | 10.94 |
| Apr 30, 2024 | 11.00 | -0.46 | -4.01% | 11.46 | 11.84 | 10.95 |
| Apr 29, 2024 | 11.80 | 0.11 | 0.94% | 11.69 | 12.59 | 11.49 |
| Apr 26, 2024 | 12.35 | 0.84 | 7.30% | 11.51 | 12.40 | 11.31 |
| Apr 25, 2024 | 11.64 | 0.38 | 3.37% | 11.26 | 11.76 | 11.08 |
| Apr 24, 2024 | 11.61 | 0.48 | 4.31% | 11.13 | 11.99 | 11.03 |
| Apr 23, 2024 | 11.21 | 0.17 | 1.54% | 11.04 | 11.84 | 11.03 |
| Apr 22, 2024 | 11.21 | -0.59 | -5.00% | 11.80 | 11.82 | 10.85 |
| Apr 19, 2024 | 12.02 | 0.54 | 4.70% | 11.48 | 12.16 | 11.48 |
| Apr 18, 2024 | 11.62 | -0.12 | -1.02% | 11.74 | 12.23 | 11.51 |
| Apr 17, 2024 | 11.70 | -0.77 | -6.17% | 12.47 | 12.91 | 11.62 |
| Apr 16, 2024 | 12.42 | 0.47 | 3.93% | 11.95 | 12.72 | 11.79 |
| Apr 15, 2024 | 12.18 | -0.51 | -4.02% | 12.69 | 12.80 | 11.98 |
| Apr 12, 2024 | 12.75 | -0.51 | -3.85% | 13.26 | 13.76 | 12.50 |
| Apr 11, 2024 | 13.48 | 0.72 | 5.64% | 12.76 | 13.50 | 12.40 |
| Apr 10, 2024 | 12.72 | 0.44 | 3.58% | 12.28 | 12.96 | 12.28 |
| Apr 9, 2024 | 12.79 | -0.33 | -2.52% | 13.12 | 13.21 | 12.13 |
| Apr 8, 2024 | 12.98 | 0.34 | 2.69% | 12.64 | 13.41 | 12.46 |
| Apr 5, 2024 | 12.55 | 0.77 | 6.54% | 11.78 | 12.79 | 11.78 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Stoke Therapeutics, Inc. Company profile
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. is a biotechnology company. It focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. It is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. It focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. It utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Stoke Therapeutics Inc revenues was not reported. Net loss increased 64% to $85.8M. Higher net loss reflects Research and development - Balancing val increase of 58% to $48M (expense), Stock-based Compensation in SGA increase from $3.9M to $10.2M (expense), General and administrative - Balancing increase of 28% to $21.7M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
45 Wiggins Avenue
BEDFORD
MASSACHUSETTS 01730
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com